{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-287960","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2021-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.760917+00:00","generated_at":"2026-06-29T00:28:01.884428+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Lyell Immunopharma Chair Dr. Richard Klausner takes medical leave; Friedman named interim Chair","bullets":["Dr. Richard Klausner takes temporary medical leave; expected return early 2022. Resigns as Executive Chairman effective Oct 1, 2022 but remains Chair.","Cathy Friedman, lead independent director, appointed interim Chair of Board during Klausner's absence.","Company states leave will not impact IND timelines (four submissions by end 2022) or corporate objectives.","Klausner issued a letter expressing confidence in management and team to continue mission during his leave."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-287960","json":"https://secwatch.observer/filing/0001193125-21-287960.json","markdown":"https://secwatch.observer/filing/0001193125-21-287960.md","text":"https://secwatch.observer/filing/0001193125-21-287960.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000119312521287960/0001193125-21-287960-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000119312521287960/d237206d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T00:28:01.884428+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e2cedd99e6","claim":"Dr. Richard Klausner resigned as Chair of the Board at Lyell Immunopharma, Inc..","evidence_excerpt":"On September 29, 2021, Dr. Richard Klausner, the Chair of the Board of Directors (the “Board”) of Lyell Immunopharma, Inc. (the “Company”) informed the Company that (a) he will take a temporary medical leave of absence and is expected to return in early 2022 (the “Leave”) and (b) he will also be resigning from his position as Executive Chairman of the Company and will no longer be an employee, effective October 1, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312521287960/0001193125-21-287960-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chair of the Board"}],"fact_type":"executive_change"},{"claim_id":"ec3e229ae5","claim":"Cathy Friedman was elected as interim Chair of the Board at Lyell Immunopharma, Inc..","evidence_excerpt":"The Board has elected Cathy Friedman, its lead independent director, to serve as the interim Chair of the Board during Dr. Klausner’s absence.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312521287960/0001193125-21-287960-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"interim Chair of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}